Item Details
ANI Pharmaceuticals makes $540 million bid for rare disease company
ANI Pharmaceuticals has made an offer worth approximately $540 million for Sweden's Egetis Therapeutics, which develops treatments for rare diseases. HPC can identify pharmaceutical distributors, healthcare investors and specialist medical businesses interested in international partnerships and acquisitions.
Get in Touch
We’ll get back to you shortly.